All relevant data and code used to reproduce the study findings are available at (<https://github.com/UF-IDD/Fluscape_Paired_Serology>).

Introduction {#sec001}
============

Seasonal influenza remains a ubiquitous threat to human health. It is estimated to kill between 291,000 and 645,000 people each year worldwide \[[@ppat.1008635.ref001]\]. Through the process of antigenic drift, antigenically novel strains replace previously circulating viruses every few influenza seasons \[[@ppat.1008635.ref002]\]. As a result, people can be infected multiple times over a lifetime \[[@ppat.1008635.ref003]\]. Each of these infections leaves a mark on a person's immune system, and the accumulation of antibody responses over a life course leads to complex individual antibody profiles reflecting both recent and past exposures \[[@ppat.1008635.ref003]--[@ppat.1008635.ref006]\]. A growing body of evidence suggests that the order and timing of influenza exposures shape the immune response in ways that may affect morbidity and mortality \[[@ppat.1008635.ref003],[@ppat.1008635.ref007]\], particularly when encountering novel (i.e. pandemic or potentially pandemic) strains \[[@ppat.1008635.ref008]\], yet a comprehensive quantitative description of how past exposure to multiple strains shapes infection risk remains elusive.

Historically, most studies have focused on measuring antibodies to a single strain or small set of strains of a subtype, either to measure the incidence of influenza through changes in titers \[[@ppat.1008635.ref009]--[@ppat.1008635.ref011]\] or as a proxy for immunity (e.g., as an endpoint in vaccine efficacy studies) \[[@ppat.1008635.ref012]--[@ppat.1008635.ref015]\]. Exceptions do exist, and studies of multi-strain dynamics after immunological challenge date back to at least 1941 \[[@ppat.1008635.ref016],[@ppat.1008635.ref017]\]. However, historically, few analytical approaches were available with which to interpret these complex data. In recent years there has been increasing interest in measuring and interpreting the breadth and strength of antigenic profiles across a diverse set of influenza strains \[[@ppat.1008635.ref004],[@ppat.1008635.ref007]\]. It is believed to provide a more nuanced picture of the humoral immune response to influenza than measuring titers to single strains (i.e. homologous titers), while the quantitative role of past exposures in determining risk of future infections and subsequent immune responses is still unclear.

Here, we describe paired antibody profiles measured at two time points (baseline from 2009 to 2011 and follow-up from 2014 to 2015), roughly four years apart, in a large sample of individuals from an ongoing cohort study in Guangzhou, Guangdong Province, China \[[@ppat.1008635.ref018]\]. We measured immune responses to multiple chronologically ordered H3N2 influenza strains (referred to as antibody profiles) that represent the history of H3N2 circulation in humans since its emergence in 1968. We aim to determine how those profiles vary across individuals and between study visits, and to test if there exist features of these antibody profiles that are more predictive of the odds of seroconversion to recently circulating strains than homologous titers only.

Antibody responses to 21 H3N2 influenza strains were measured for each individual from sera using hemagglutination inhibition assays (HAI). The strains selected covered the period between 1968--2014, and included strains isolated at 2--3 year intervals. Strains included in the vaccine formulation and tested by Fonville et al. \[[@ppat.1008635.ref007]\] were prioritized, but when this was not possible another antigenically representative strain from that year was selected. We included two strains that were isolated in 2009 (i.e. A/Perth/2009 and A/Victoria/2009) to address the potential difference in the circulating strain and vaccine strain in that year. We described individual antibody profiles from these serological data, and introduced multiple novel metrics to summarize each individual's profile and facilitate comparisons of profiles across age and time. We also determined if summary metrics of antibody profiles improved predictions of the odds of seroconversion. We define seroconversion against strain as four-fold or greater rise in titers to that strain between baseline and follow-up, which is a commonly used indicator of influenza exposure \[[@ppat.1008635.ref014]\].

Results {#sec002}
=======

Serological data and individual antibody profiles {#sec003}
-------------------------------------------------

Both baseline (December 4, 2009 to January 22, 2011, with 44% of serum collected after the 2010 summer season started) and follow-up (June 17, 2014 to June 2, 2015, with 94% of serum collected after the 2014 summer season started) sera were available from 777 participants aged from 2 to 86 years old (age at baseline is used throughout unless otherwise noted) \[[@ppat.1008635.ref018]--[@ppat.1008635.ref020]\]. Participants giving serum were largely representative of the censused and overall study populations, with under representation of young children and over representation of participants aged 40--59 years ([S1 Table](#ppat.1008635.s019){ref-type="supplementary-material"}) \[[@ppat.1008635.ref018]\]. There were 10 participants (1.3%) who reported being vaccinated against influenza at baseline, and 5 participants (0.6%) who reported influenza vaccination between the two visits.

In total, 32,606 HAI titer readings were available, with only 28 missing out of 21 × 777 × 2 possible strain-individual-visit combinations. Figs [1](#ppat.1008635.g001){ref-type="fig"} and [S1](#ppat.1008635.s002){ref-type="supplementary-material"}shows example individual antibody profiles for an age representative subset of individuals. We defined the four strains (i.e. A/Perth/2009, A/Victoria/2009, A/Texas/2012 and A/HongKong/2014) that were isolated between the first baseline and last follow-up as "recent strains". Strains isolated prior to an individual's birth were defined as "pre-birth strains" ([Fig 1A--1C](#ppat.1008635.g001){ref-type="fig"}) and "post-birth strains" otherwise.

![Representative individual profiles of HAI titer against H3N2 strains circulating over forty years.\
(A-F): Antibody profile for each representative individual. Blue circles and red triangles represent the HAI titers against the tested strains at baseline and follow-up visit, respectively. Blue and red solid lines represent the smoothed HAI titers for serum collected from baseline and follow-up visit, respectively. Smooth splines of HAI titers on circulating years are shown in this figure for illustration purposes and not used in the subsequent analysis. Grey areas represent the baseline antibody profile. Purple and green areas indicate the increase and decrease of HAI titer at follow-up visit compared to baseline, respectively. Blue and red vertical blocks represent the duration for baseline and follow-up visit, respectively. Vertical dotted-dashed lines indicate the year of birth of the individual. Dashed and dotted lines represent the titer of 1:10 (detectable cutoff) and 1:40 (protective cutoff), respectively. Table below each panel shows the values of metrics calculated for each individual. We provided six additional profiles of HAI titers from people who were aged 40 to 60 years in [S1 Fig](#ppat.1008635.s002){ref-type="supplementary-material"}.](ppat.1008635.g001){#ppat.1008635.g001}

All individuals had detectable titers (1:10) and 95.6% of participants had titers of at least 1:40 to at least one strain at baseline ([Fig 2A and 2B](#ppat.1008635.g002){ref-type="fig"}). Across all 21 × 777 strain-individual combinations, the most commonly detected titer value was \< 1:10 at baseline (28.0%) and 1:20 and 1:40 at follow-up (22.0% and 21.8%, respectively) ([Fig 2D and 2E](#ppat.1008635.g002){ref-type="fig"}). The median of geometric mean titer (GMT) across post-birth strains was 14.3 \[interquartile range (IQR), 12.2 to 30.0) at baseline and 36.4 (IQR, 21.9 to 46.8) at follow-up ([Fig 2A and 2B](#ppat.1008635.g002){ref-type="fig"}, and [S2 Table](#ppat.1008635.s020){ref-type="supplementary-material"}). GMTs of post-birth strains \[18.3; 95% confidence interval (CI), 18.0 to 18.7\] were higher than that of pre-birth strains (9.6; 95% CI, 9.2 to 10.0) at baseline ([Fig 2A](#ppat.1008635.g002){ref-type="fig"} and [S2 Table](#ppat.1008635.s020){ref-type="supplementary-material"}). 73.9% of titers to pre-birth strains were below 1:40 at baseline (62.6% at follow-up; [Fig 2A and 2B](#ppat.1008635.g002){ref-type="fig"} and [2G and 2H](#ppat.1008635.g002){ref-type="fig"}) and the lower titers were found to these pre-birth strains with the longer intervals from isolation to birth ([S1 Fig](#ppat.1008635.s002){ref-type="supplementary-material"}). We fitted generalized additive models (GAM) to titers on age at isolation (i.e. age when the strain was isolated) and found the highest titers at a median age at isolation of 4.3 years (IQR, 2.0 to 6.9 years) across strains ([Fig 3D and 3E](#ppat.1008635.g003){ref-type="fig"}; details in [S1 Text](#ppat.1008635.s001){ref-type="supplementary-material"}). GMTs of recent strains (12.0; 95% CI, 11.6 to 12.4) were lower than that of non-recent strains (18.7; 95% CI, 18.3 to 19.0) at baseline, but were higher at follow-up \[41.5 (95% CI, 39.7 to 43.3) for recent strains and 31.3 (95% CI, 30.7 to 31.9) for non-recent strains\].

![HAI titers and differences in HAI titers between two visits against historical H3N2 strains.\
(A) and (B): HAI titers against H3N2 strains from serum collected from baseline and follow-up visit, respectively. Participants are sorted by age at baseline sampling. (C): Fold of changes of HAI titers between two visits. Cell of row *i* and column *j* represents HAI titer or differences of HAI between two visits to strain *i* for person *j*. (D-F): Distribution of HAI titers from serum collected from baseline (D), follow-up visit (E), and fold of changes between two visits (F), respectively. Distributions were plotted after grouping titers across all participants and all tested H3N2 strains. (G) Variations of HAI titers at baseline with ages of participants and the year of isolation of tested strains. Dashed lines represent birth years of the participants (same for panel H and I). (H) Variations of HAI titers at follow-up with ages of participants and the year of isolation of tested strains. (I) Variation of changes in HAI titers between the two visits with ages of participants and the year of isolation of tested strains.](ppat.1008635.g002){#ppat.1008635.g002}

![Age and HAI titer against individual H3N2 strain.\
Lines are the predicted mean HAI titer fitted from general additive model (GAM) using age at sampling (panel A to C) and age at isolation (panel D to F) as predictor, respectively. We fitted separate GAMs for HAI titers measured for serum collected from baseline (panel A and D), serum collected in follow-up visit (panel B and E) and the differences between two visits (panel C and F).](ppat.1008635.g003){#ppat.1008635.g003}

Summary metrics of antibody profiles {#sec004}
------------------------------------

We hypothesized that features of an antibody profile determine an individual's odds of seroconversion over and above homologous titer. We developed several metrics aimed at summarizing the information in individuals', often complex, antibody profiles ([Fig 4](#ppat.1008635.g004){ref-type="fig"}). We estimated: the *area under the curve* (AUC) for each antibody profile (i.e. the integral of an individual's measured log titers); the *width* (W~Z~) of an individual's antibody titer above a threshold *z* (i.e. the proportion of the profile above that threshold; W~40~ for protective threshold and W~10~ for detectable threshold); and the *average titer year* (ATY) of each antibody profile (i.e. the average of strain isolation years weighted by their titer) (see [Methods](#sec013){ref-type="sec"}). We hypothesized that these features of antibody profiles captured biologically relevant properties of the immune response to H3N2; in particular, overall levels of antibody mediated immunity (for AUC), the breadth of antibody mediated immune response (for W~40~ and W~10~) and temporal center of mass of H3N2 immunity (for ATY). In most analyses, we use normalized versions of these metrics (i.e. nAUC, nW~40~, nW~10~, nATY) to adjust for differences between individuals in the number of possibly exposed strains given their ages (i.e. individuals could not have been exposed to pre-birth strains) (see [Methods](#sec013){ref-type="sec"}. Non-normalized analysis included in [S1 Text](#ppat.1008635.s001){ref-type="supplementary-material"}, [S2 Fig](#ppat.1008635.s003){ref-type="supplementary-material"}, [S3](#ppat.1008635.s021){ref-type="supplementary-material"} and [S4](#ppat.1008635.s022){ref-type="supplementary-material"} Tables).

![The normalized area under the curve (nAUC), width above 1:40 (nW~40~) and average titer years (nATY) varying with age.\
Metrics were calculated using post-birth strains and normalized by the number of post-birth strains. Blue and red represent the metrics measured for serum collected from baseline and follow-up visit, respectively. Purple indicates the differences in metrics between the two visits. Solid lines are predictions from a generalized additive model and the colored dashed lines represent the corresponding 95% confidence intervals. (A) Demonstration of nAUC for one participant as an example. The same participant, who was aged 73 years old at baseline, is used for panel E and I. (B) Age and nAUC at baseline. (C) Age and nAUC at follow-up. (D) Age and changes in nAUC between the two visits. (E) Demonstration of nW~40~ for one participant as an example. Solid points are the years that contributed to calculating width. (F) Age and nW~40~ at baseline. (G) Age and nW~40~ at follow-up. (H) Age and changes in nW~40~ between the visits. (I) Demonstration of nATY for one participant as an example. (J) Age and nATY at baseline. The sloping black dotted lines indicate the year of birth of participants and the black dashed lines indicate the unweighted average isolation year of post-birth strains given age on x-axis (same for panel K and L). (K) Age and nATY at follow-up. (L) Age and changes in nATY between the visits.](ppat.1008635.g004){#ppat.1008635.g004}

We calculated nAUC, nW~40~, nW~10~, nATY for each participant, and fitted generalized additive models using a spline on age to estimate the association of these metrics with participant age. The nAUC of titers increased with participant age, peaking at \~ 20 years of age for both visits and gradually decreasing to a low at \~ 50 years of age ([Fig 4B and 4C](#ppat.1008635.g004){ref-type="fig"}). The average nAUC among participants aged 50 years old was estimated to be lower than that among participants aged 20 years old \[ratio: 0.48 (95% CI, 0.42 to 0.53; 95% CI from 1000 bootstraps and see [Methods](#sec013){ref-type="sec"} for details) for baseline and 0.59 (95% CI, 0.53 to 0.67) for follow-up\]. After the age of 70, nAUC started to increase.

The width of HAI titers above protective titer levels (nW~40~) illustrated an increasing trend with age grows until approximately 15 years of age at the time of sample collection, peaking at 60.3% and 80.1% at baseline and follow-up, respectively ([Fig 4F and 4G](#ppat.1008635.g004){ref-type="fig"}). There was a more distinct drop in nW~40~ among participants aged 50 years old \[ratio of nW~40~ at 50 to nW~40~ at 15: 0.28 (95% CI, 0.25 to 0.29; 95% CI from 1000 bootstraps and see [Methods](#sec013){ref-type="sec"} for details) and 0.46 (95% CI, 0.43 to 0.49) for baseline and follow-up, respectively\], compared to the drop in nW~10~ \[ratio of nW~10~ at 50 to nW~10~ at 15: 0.78 (95% CI, 0.75 to 0.79) and 0.94 (95% CI, 0.90 to 0.97)\] ([S3 Fig](#ppat.1008635.s004){ref-type="supplementary-material"}). An uptick of widths among those older than 60 years was observed for both cutoffs (Figs [4](#ppat.1008635.g004){ref-type="fig"} and [S3](#ppat.1008635.s021){ref-type="supplementary-material"}).

The intent of nATY is to help us understand how immunity to strains circulating at different times contributes to the overall immune profile. At the extremes, if the antibody response was completely dominated by early infections, nATY would track with birth year. However, we hypothesized that people constantly generate updated antibody responses to newly encountered strains during their lifetimes, and nATY would track with the midpoint of the post-birth strains (i.e. unweighted average isolation year of post-birth strains). Our empirical observations are in line with our hypothesis; baseline nATY moved away from birth year at a rate of 0.50 years for every additional year of life (0.45 years at follow-up) and tracked the midpoint of the post-birth strains ([Fig 4J and 4K](#ppat.1008635.g004){ref-type="fig"}). The average nATY among people aged 40 years or older, who have been exposed to all tested strains, stayed unchanged and centered on the unweighted average isolation year of all tested strains. The follow-up nATY tended to skew 2.4 years to more recent years than the unweighted average isolation year among those people who seroconverted to the recent strains (t-test, p \< 0.01).

Changes in antibody profiles between the two visits {#sec005}
---------------------------------------------------

Across our cohort, changes, particularly increases, in titer were seen across all strains, including strains that have long been extinct (Figs [2C--2F](#ppat.1008635.g002){ref-type="fig"} and [5A](#ppat.1008635.g005){ref-type="fig"}). 97.9% of people experienced a rise against one or more strains. 73.7% showed a 4-fold or greater titer increase (seroconversion) to one or more, with increased risk of occurring in strains circulating after 1998 compared to A/HongKong/1968 \[odds ratio (OR) ranges from 2.7 (95% CI, 2.0 to 3.9) to 16.4 (95% CI, 12.0 to 22.6) across these strains\] ([S4 Fig](#ppat.1008635.s005){ref-type="supplementary-material"}), i.e. strains more antigenically similar to ones with which the participant could have been infected. The largest increases in HAI titers were detected for four recent strains ([Fig 5B](#ppat.1008635.g005){ref-type="fig"}), and there was high-correlation in seroconversions; 63.1% of those who seroconverted to one or more strains seroconverted to all four strains. ([S5 Fig](#ppat.1008635.s006){ref-type="supplementary-material"}). Meanwhile, a minority of people (18.3%) showed a decrease in titer to one or more strains, likely due to transient boosting from exposures prior to baseline sampling \[[@ppat.1008635.ref005],[@ppat.1008635.ref021]\].

![Changes in antibody profiles between visits.\
(A) Geometric mean titers (GMT) by strain. Blue and red points represent GMT at baseline and follow-up, respectively. (B) Distribution of changes in titers by strain. We divided the changes in titers into four categories, i.e. decrease (green), no change (grey), two-fold increase (light purple) and four-fold change (seroconversion, dark purple).](ppat.1008635.g005){#ppat.1008635.g005}

Effect of pre-existing immunity on seroconversion to recent strains {#sec006}
-------------------------------------------------------------------

Pre-existing, homologous titer to circulating strains is a well-described predictor of odds of seroconversion \[[@ppat.1008635.ref014]\], which is confirmed in our study (Tables [1](#ppat.1008635.t001){ref-type="table"}, [S3](#ppat.1008635.s004){ref-type="supplementary-material"} and [S4](#ppat.1008635.s022){ref-type="supplementary-material"}). However, we hypothesized that including metrics of antibody profiles that integrate previous exposure history would further improve predictions of the odds of seroconversion. Therefore, we examined the association between the odds of seroconversion with age at baseline sampling, pre-existing, homologous titer to outcome strains (the *i*th strain), titer to the *i-1*th strain, and summary metrics (i.e. nAUC, nW~10~, nW~40~, and nATY) of strains up to and including the *i-2*th strain ("immunity of non-recent strains" hereafter). A greater frequency of seroconversion to an examined strain is expected when the estimated odds ratio (OR) of the above-mentioned predictors is greater than 1 ([Table 1](#ppat.1008635.t001){ref-type="table"}). We found including nAUC or nW~40~ improved the deviance explained (e.g. 11% increase in deviance explained after including nAUC for A/Texas/2012; Models 1--2 in [Table 1](#ppat.1008635.t001){ref-type="table"}) and Akaike information criterion (AIC) ([S6 Fig](#ppat.1008635.s007){ref-type="supplementary-material"}) of the models. After adjustment for pre-existing titer to strain *i*, we found pre-existing nAUC and nW~40~ were each positively associated with seroconversion (Tables [1](#ppat.1008635.t001){ref-type="table"}, [S3](#ppat.1008635.s004){ref-type="supplementary-material"} and [S5](#ppat.1008635.s023){ref-type="supplementary-material"}). Taking A/Texas/2012 as an example, pre-existing titer to A/Texas/2012 was negatively associated with the odds of seroconversion (OR: 0.45; 95% CI, 0.35 to 0.57; Model 3 in [Table 1](#ppat.1008635.t001){ref-type="table"}), while there was an increased odds of seroconversion associated with higher pre-existing nAUC (OR: 1.21; 95% CI, 1.10 to 1.34) and nW~40~ (OR: 5.53; 95% CI, 2.15 to 14.57).

10.1371/journal.ppat.1008635.t001

###### Associations between pre-existing immunity and seroconversion to four recent strains.

![](ppat.1008635.t001){#ppat.1008635.t001g}

                                                                  Adjusted odds ratio (95% confidence interval)                                                                                                                                
  --------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------
  **Model 1**                                                                                                                                                                                                                                  
  Age at sampling                                                 1.00 (0.99, 1.01)                                        0.99 (0.98, 1.00)                                         0.99 (0.98, 1.00)[\*](#t001fn003){ref-type="table-fn"}    1.00 (0.99, 1.01)
  Titer to strain i[^a^](#t001fn001){ref-type="table-fn"}         0.43 (0.34, 0.54)[\*](#t001fn003){ref-type="table-fn"}   0.51 (0.42, 0.60)[\*](#t001fn003){ref-type="table-fn"}    0.49 (0.38, 0.61)[\*](#t001fn003){ref-type="table-fn"}    0.70 (0.56, 0.85)[\*](#t001fn003){ref-type="table-fn"}
  Titer to strain i-*1*[^*a*^](#t001fn001){ref-type="table-fn"}   1.30 (1.10, 1.55)[\*](#t001fn003){ref-type="table-fn"}   1.03 (0.87, 1.22)                                         1.06 (0.85, 1.32)                                         0.93 (0.79, 1.09)
  Deviance explained                                              7.5%                                                     12.9%                                                     12.6%                                                     4.0%
  **Model 2**                                                                                                                                                                                                                                  
  Age at sampling                                                 1.01 (1.00, 1.02)                                        1.00 (0.99, 1.01)                                         1.00 (0.99, 1.01)                                         1.00 (0.99, 1.01)
  Titer to strain i                                               0.42 (0.33, 0.53)[\*](#t001fn003){ref-type="table-fn"}   0.48 (0.40, 0.57)[\*](#t001fn003){ref-type="table-fn"}    0.45 (0.35, 0.57)[\*](#t001fn003){ref-type="table-fn"}    0.67 (0.54, 0.82)[\*](#t001fn003){ref-type="table-fn"}
  Titer to strain i-*1*                                           1.21 (1.02, 1.44)[\*](#t001fn003){ref-type="table-fn"}   0.97 (0.82, 1.16)                                         0.97 (0.78, 1.22)                                         0.85 (0.71, 1.01)
  AUC[^b^](#t001fn002){ref-type="table-fn"}                       1.14 (1.05, 1.24)[\*](#t001fn003){ref-type="table-fn"}   1.17 (1.07, 1.29)[\*](#t001fn003){ref-type="table-fn"}    1.21 (1.10, 1.34)[\*](#t001fn003){ref-type="table-fn"}    1.17 (1.07, 1.29)[\*](#t001fn003){ref-type="table-fn"}
  Deviance explained                                              8.3%                                                     14.0%                                                     14.0%                                                     5.0%
  **Model 3**                                                                                                                                                                                                                                  
  Age at sampling                                                 1.00 (0.99, 1.02)                                        1.00 (0.99, 1.01)                                         1.00 (0.99, 1.01)                                         1.00 (0.99, 1.01)
  Titer to strain *i*                                             0.43 (0.34, 0.54)[\*](#t001fn003){ref-type="table-fn"}   0.49 (0.40, 0.58)[\*](#t001fn003){ref-type="table-fn"}    0.45 (0.35, 0.57)[\*](#t001fn003){ref-type="table-fn"}    0.68 (0.55, 0.84)[\*](#t001fn003){ref-type="table-fn"}
  Titer to strain *i-1*                                           1.24 (1.04, 1.47)[\*](#t001fn003){ref-type="table-fn"}   0.98 (0.83, 1.17)                                         1.00 (0.80, 1.25)                                         0.88 (0.74, 1.05)
  Width, cut off 1:40[^b^](#t001fn002){ref-type="table-fn"}       2.86 (1.20, 6.92)[\*](#t001fn003){ref-type="table-fn"}   4.50 (1.77, 11.71)[\*](#t001fn003){ref-type="table-fn"}   5.53 (2.15, 14.57)[\*](#t001fn003){ref-type="table-fn"}   2.79 (1.13, 6.98)\*
  Deviance explained                                              8.0%                                                     13.9%                                                     13.8%                                                     4.5%

^a^ Strain *i* refers to the strain that was examined for seroconversion, and strain *i-1* refers to the most recent strain isolated prior to strain *i*. E.g. when using seroconversion to A/Perth/2009 as outcome, strain *i* and *i-1* will be A/Perth/2009 and A/Brisbane/2007, respectively.

^b^ Metrics were calculated using titers to strains isolated after the birth of the participants and before the year that strain *i-1* was isolated. Adjustment was then performed by standardizing the metrics with the number of post-birth strains.

\* Statistical significant level of 0.05.

We did not observe a positive association between immunity to non-recent strains and seroconversion to recent strains in the univariable analysis ([S6 Table](#ppat.1008635.s024){ref-type="supplementary-material"}), which was expected given that people with higher immunity of non-recent strains tended to have higher homologous titers to recent strains ([S7 Table](#ppat.1008635.s025){ref-type="supplementary-material"}). We therefore performed mediation analysis under the hypothesis ([S7 Fig](#ppat.1008635.s008){ref-type="supplementary-material"}) that pre-existing immunity to pre-exposures imposes both indirect effect mediated by titer to strain *i* and direct effect on seroconversion to strain *i*. Results suggested both AUC and nW~40~ had negative indirect effects and positive direct effects (except for nW~40~ on A/HongKong/2014) on seroconversion to strain *i*, which yielded non-significant or marginally negative total effects ([S8 Fig](#ppat.1008635.s009){ref-type="supplementary-material"}).

Discussion {#sec007}
==========

Life course exposures continually shape antibody profiles of influenza {#sec008}
----------------------------------------------------------------------

We found an individual's antibody profile is dynamically updated across time. A majority of participants experienced seroconversion to recent strains and a minority of participants showed decreases in antibody profiles due to the transient antibody dynamics. Therefore, we expected that titers to recent strains would vary over the course of our study, but that, whereas titers to non-recent strains would to be relatively constant and when variation did exist, it would be in a random direction. However, we found that antibody titers to non-recent strains overwhelmingly increased (Figs [2C](#ppat.1008635.g002){ref-type="fig"} and [4B](#ppat.1008635.g004){ref-type="fig"}), inconsistent with random variation ([S9 Fig](#ppat.1008635.s010){ref-type="supplementary-material"}) suggesting that most increases, even those to non-recent strains, can be attributed to exposure to circulating strains. Of note, the HI titers and rises in titers to A/HongKong/2014 were relatively lower compared to other recent strains, which may due to low assay sensitivity to detect HI titers to Clade 3c.2a strains and/or the co-circulation with the Clade 3c.3a strains (e.g. A/Switzerland/2013). Though titer to non-recent strains in general increased between the two samples, the shape of each person's antibody profile was highly consistent between visits (median Pearson\'s correlation 0.90; IQR, 0.82 to 0.94). This result is similar to previously described results from 5 landscapes for 69 individuals \[[@ppat.1008635.ref007]\], suggesting that individuals maintain patterns of relative titer across historical strains, even while acquiring antibodies due to new exposures.

We expect individuals of different ages to show different antibody profiles due to differences in lifetime influenza exposures. However, we found that our summary metrics did not monotonically increase with age. There is a gradual increase in the overall (nAUC) and breadth of immunity (nW~40~) throughout childhood consistent with the accumulation of exposures (Figs [3](#ppat.1008635.g003){ref-type="fig"}, [4J and 4K](#ppat.1008635.g004){ref-type="fig"}) \[[@ppat.1008635.ref003]--[@ppat.1008635.ref005]\]. The observed decrease in nAUC and nW~40~ among people aged 40 to 50 and age-independent changes in these metrics ([Fig 4D and 4H](#ppat.1008635.g004){ref-type="fig"}) could suggest low HAI antibody among this age group, which could be due to high non-specific immune responses \[e.g. antibodies against HA stalk and neuraminidase (NA) and cellular immune responses; \[[@ppat.1008635.ref021]--[@ppat.1008635.ref025]\]\]. These non-specific immunities, which may accumulate over multiple exposures and are not measured in our assay, could prevent people from being infected and producing updated, strain specific HA responses \[[@ppat.1008635.ref022],[@ppat.1008635.ref023],[@ppat.1008635.ref026]\].

Our hypotheses about the mechanisms driving age patterns in antibody profiles implicitly assume repeated, regular exposure to influenza throughout life. Consistent with this assumption, our findings during this four-year period suggested a nearly universal exposure to H3N2 in this cohort (Figs [2C](#ppat.1008635.g002){ref-type="fig"} and [4D](#ppat.1008635.g004){ref-type="fig"}), agreeing with observations of high H3N2 incidence during this period with particularly large numbers of cases in 2011--12 that was covered by our study period \[[@ppat.1008635.ref019],[@ppat.1008635.ref020]\]. This is consistent with other reports that the H1N1 pandemic which occurred just before or just after the beginning of our baseline sampling lead to a period of low H3N2 incidence, followed by a large resurgence of H3N2 in the period 2011--2012 \[[@ppat.1008635.ref027]\]. 24.1% of our participants only had two-fold increase to the tested strains, suggesting widely existing exposures but probably not infections.

Future immune responses to influenza are driven by antibody profiles {#sec009}
--------------------------------------------------------------------

Our work further quantified the complex role that antibody profiles play in future immune responses to influenza. We confirmed the prominent role of pre-existing, homologous titers in determining the odds of seroconversion. However, we found that participants who had higher immunity to previously exposed strains were more likely to experience seroconversion to recent strains after adjusting for homologous titer. These findings were not affected by age, self-reported vaccination or collection time ([S10](#ppat.1008635.s011){ref-type="supplementary-material"} and [S11](#ppat.1008635.s012){ref-type="supplementary-material"} Figs and [S5](#ppat.1008635.s023){ref-type="supplementary-material"}, [S8](#ppat.1008635.s026){ref-type="supplementary-material"}--[S10](#ppat.1008635.s028){ref-type="supplementary-material"} Tables). Given individuals with high immunity to non-recent strains tended to have higher homologous titers ([S6](#ppat.1008635.s024){ref-type="supplementary-material"} and [S7](#ppat.1008635.s025){ref-type="supplementary-material"} Tables), we investigated whether the effect of immunity to non-recent strains was mediated by homologous titer ([S7](#ppat.1008635.s008){ref-type="supplementary-material"} and [S8](#ppat.1008635.s009){ref-type="supplementary-material"} Figs; detailed in [S1 Text](#ppat.1008635.s001){ref-type="supplementary-material"}) and found that pre-existing immunity to non-recent strains imposes a positive direct effect on the odds of seroconversion to recent strains but a negative, homologous titer mediated, indirect effect.

The mechanism behind the positive association between immunity to non-recent strains and seroconversion to recent strains is unclear. One plausible hypothesis is that a subset of people tend to have a more vigorous titer response across strains (e.g. individual heterogeneity in immune responses). This is supported by our data that positive association can still be detected when using titer to an older strain, instead of the summary metric of antibody profiles, as the proxy of immunity to non-recent strains in models shown in [Table 1](#ppat.1008635.t001){ref-type="table"} ([S12 Fig](#ppat.1008635.s013){ref-type="supplementary-material"}). Another plausible hypothesis is that non-HAI immunity that was acquired from previous infections (e.g. antibody to HA stalk and NA and cellular immune responses) could blunt the production of strain-specific antibody upon exposure to circulating strains \[[@ppat.1008635.ref021]--[@ppat.1008635.ref024]\], thus reducing the HAI titers to the circulating strains and increasing the probability of seroconversion. High antibody to non-recent strains could indicate individuals who have not experienced infection in recent times \[e.g. low strain-specific antibody to currently circulating strains due to temporary protection from last infection \[[@ppat.1008635.ref026],[@ppat.1008635.ref028],[@ppat.1008635.ref029]\]\]. Homologous HAI titers may reflect the combined binding ability of antibody targeting the tested antigen as well as antibody targeting previously encountered epitopes, and high antibody titers to non-recent strains may indicate particular distributions of these two that are less protective.

Life course immunity of influenza provides new opportunities in influenza studies {#sec010}
---------------------------------------------------------------------------------

Previous work on mapping antigenic distance of evolving strains and characterization of life course immunity has changed how we approach studies of immunity to influenza \[[@ppat.1008635.ref002],[@ppat.1008635.ref007]\]. The summary metrics we developed allow efficient characterization of profiles that are amenable to broad use in the analysis. In particular, although the age patterns in AUC and widths are similar, width is more likely to capture specific responses to a HA and therefore the two metrics would diverge in a person who does not have strong responses to a strain and its antigenically relatives. With these metrics, we integrated information of life course HAI antibody mediated immunity to influenza that accounted for complex exposure histories and cross-reactions between influenza strains. These metrics should help to quantify the life course of non-HAI immunity that were not measured by our assay, and the interactions between infection events and immunity to influenza through life.

Limitations {#sec011}
-----------

Our study has several limitations. First, we didn't include strain from Clade 2c.3a, which was co-circulating with A/HongKong/2014-like strain in the 2014--2015 season \[[@ppat.1008635.ref030]\]. Our results seem to be robust as we found similar effects of immunity to previous exposures on the seroconversion to four recent strains ([Table 1](#ppat.1008635.t001){ref-type="table"}). Second, between-subtype interactions have not been incorporated into the work, especially interactions with H1N1 which might confer temporary protection against H3N2 \[[@ppat.1008635.ref031]\]. We, however, observed inconsistent responses to H3N2 strains that were isolated after the 1977 epidemic and 2009 pandemic of H1N1 ([Fig 2B and 2H](#ppat.1008635.g002){ref-type="fig"}).

Conclusion {#sec012}
----------

We developed multiple summary metrics to integrate information of antibody profiles, which enabled us to further demonstrate clear age patterns of these profiles. We found accumulation of immunity to H3N2 during the first twenty years of life, followed by reductions among 40--50 years old. These age patterns in antibody profiles are likely to be driven by continual exposure to influenza; our study suggested nearly universal exposures during a four-year interval. Meanwhile, antibody profiles were found to provide more information than homologous titers in predicting temporal changes in influenza immunity. In particular, higher immunity to older strains was found associated with increased odds of seroconversion to the currently circulating strains, which mechanism remains unclear.

Materials and methods {#sec013}
=====================

Ethics statements {#sec014}
-----------------

Study protocols and instruments were approved by the following institutional review boards: Johns Hopkins Bloomberg School of Public Health, University of Florida, University of Liverpool, University of Hong Kong, Guangzhou No. 12 Hospital, and Shantou University. Written informed consent was obtained from all participants over 12 years old; verbal assent was obtained from participants 12 years old or younger. Written permission of a legally authorized representative was obtained for all participants under 18 years old.

Cohort profile {#sec015}
--------------

The Fluscape study is an ongoing cohort study in and around Guangzhou City in southern China that collects sera from consenting participants at regular intervals (roughly annually), as well as information on demographics. The methods and study population have been described in detail elsewhere \[[@ppat.1008635.ref018]\]. Briefly, 40 locations were randomly selected from a spatial transect extending to the northeast from the center of Guangzhou. In each location 20 houses were randomly selected and all consenting residents over 2 years of age were enrolled in the study. When households left the study, they were replaced by new randomly selected households to maintain a population of 20 households per location.

We collected serum from participants at two time points, i.e. baseline (2009 to 2011) and follow-up (2014--2015). Serum from both visits were available from 777 participants out of 2,767 total participants (across both visits, [S1 Table](#ppat.1008635.s019){ref-type="supplementary-material"}), of which 763 participants had interpretable titers for all 21 H3N2 strains ([Fig 2A--2C](#ppat.1008635.g002){ref-type="fig"}, 14 participants had uninterpretable results for 5 strains). Age at the time of the baseline ranged from 2 to 86 years old, with over representation of participants aged 40--59 years compared to the Chinese population according to the 2009 census (51.4% vs. 31.6%) \[[@ppat.1008635.ref018]\].

Laboratory testing {#sec016}
------------------

Blood samples were kept at 4°C until processing on the day of collection. Serum is extracted from these samples and frozen at -80°C until testing. For all individuals recruited at both baseline visit (4 December 2009 to 22 January 2011) and follow-up visit (17 June 2014 to 2 June 2015) we measured hemagglutination inhibition (HAI) titers for antibodies against a panel of 21 strains of H3N2 influenza spanning the history of the virus since its emergence in humans in 1968 (A/Hong Kong/1968, X31, A/England/1972, A/Victoria/1975, A/Texas/1977, A/Bangkok/1979, A/Philippines/1982, A/Mississippi/1985, A/Sichuan/1987, A/Beijing/1989, A/Beijing/1992, A/Wuhan/1995, A/Victoria/1998, A/Fujian/2000, A/Fujian/2002, A/California/2004, A/Brisbane/2007, A/Perth/2009, A/Victoria/2009, A/Texas/2012, A/Hong Kong/2014). The 50% tissue culture infectious dose (TCID50) for each virus was determined on Madin‐Darby canine kidney (MDCK) cells \[[@ppat.1008635.ref032]\]. For each strain-individual pair, HAI titers were determined by two-fold serial dilutions from 1:10 to 1:1280 conducted in 96-well microtiter plates with 0.5% turkey erythrocytes. Sera from the two visits were tested side by side on the same plate, and confirmatory samples collected in 2014 sera were tested on a separate plate. The reciprocal of the highest dilution where hemagglutination does not occur is reported as the titer. There were 28 missing (for 14 individuals and 5 strains) out of 32,636 strain-individual-visit combinations, which were due to inadequate sera remaining or inconclusive readings.

Analytic methods {#sec017}
----------------

For analysis, individuals with undetected titers are assumed to have a titer of 5, and all titers are transformed to the log-scale. Specifically, we transform titers based on the formula y = log2(x/5) where x is the measured titer, which results in a 0 for undetectable titers and a 1 unit rise in titer for each 2-fold increase (so 10 = 1, 20 = 2, 40 = 3, etc.). In figures, measures are transformed back to the arithmetic scale for clarity; but all statistics are presented on this scale. Geometric mean titer (GMT) was calculated as the mean of log-titer and transformed back to the arithmetic scale. 95% confidence intervals (CIs) were calculated using student t tests assuming the log-titer follows a normal distribution. Age at baseline sampling is defined as the time difference between the year of baseline and the year of birth; age at isolation is calculated as the year when the tested strain was isolated minus the year of birth of the participant.

### Age patterns in strain-specific titers {#sec018}

We fitted univariable GAMs to the measured log-titers on the participants' age at baseline sampling (i.e. participant age when serum was collected at baseline sampling) and age at isolation \[i.e. participants' ages when strains were isolated \[[@ppat.1008635.ref004]\]\], respectively to examine the strain-independent age patterns of HAI titers ([Fig 3](#ppat.1008635.g003){ref-type="fig"}). We fitted separate models to each strain. From each fitted model, we derived the age at sampling or age at isolation when the titer to each strain is predicted to be the highest and characterized the range across strains.

### Summary metrics {#sec019}

Individual antibody profiles were constructed using each individual's HAI titers against 21 tested H3N2 strains which were sorted in chronological order. We characterized the shape of these individual antibody profiles using a number of statistics ([Fig 4](#ppat.1008635.g004){ref-type="fig"}) which are proposed to approximately estimate the area under the antigenic landscape surface (Area Under the Curve, AUC), the breadth of antibody profile (Width, W), where the breadth is calculated above either detective (1:10) or protective threshold (1:40), and the temporal targeting of antibody profile by the measured HAI titer values (Averaged Titer Year, ATY). The statistics are calculated as follows:

1.  *Area Under the Curve (*AUC*)*: We estimated the area under the curve of antibody profile as: $$AUC_{j,v} = {\sum\limits_{i = 1}^{M - 1}\frac{y_{i,j,v} + y_{i + 1,j,v}}{2}}\left( t_{i + 1} - t_{i} \right)$$ where *AUC*~*j*,*v*~ is the area-under the curve of titers by time for person *j* and visit *v*, *M* is the total number of included strains, *y*~*i*,*j*,*v*~ is participant *j*'s log-titer against strain *i* at visit *v*, and *t*~*i*~ is the time of isolation of strain *i*.

2.  *Width (*W*)*: We define the width of the curve to be the proportion of time during which the antibody profile that is greater than or equal to some predefined antibody titer cutoff, Z. Here we focus on detectable titers (*W*~10~, *Z* = 1:10), and protective titers (*W*~40~), based on the commonly used cutoff *Z* = 1:40. When performing the calculation, we transformed the threshold to log-scale based on the formula z = log2(Z/5). Hence, $$W_{Z,j,v} = {\sum\limits_{i = 1}^{M - 1}{W_{Z,j,v}\left( t_{i},t_{i} + 1 \right)}}$$ where: $$W_{Z,j,v}\left( {t_{i},t_{i + 1}} \right) = \left\{ \begin{array}{r}
    {t_{i + 1} - t_{i},\quad y_{i + 1,j,v} \geq z\ and\ y_{i,j,v} \geq z} \\
    {0,\quad y_{i + 1,j,v} < z\ and\ y_{i,j,v} < z} \\
    {\frac{\left( {y_{i + 1,j,v} - z} \right)\left( {t_{i + 1} - t_{i}} \right)}{y_{i + 1,j,v} - y_{i,j,v}},\quad y_{i + 1,j,v} \geq z\ and\ y_{i,j,v} < z} \\
    {\frac{\left( {z - y_{i,j,v}} \right)\left( {t_{i + 1} - t_{i}} \right)}{y_{i + 1,j,v} - y_{i,j,v}},\quad y_{i + 1,j,v} < z\ and\ y_{i,j,v} \geq z} \\
    \end{array} \right.$$

    When titers to all strains are above the threshold *z*, the width for an individual given the tested strains is at its maximum: $$max\left( W_{Z,j,v} \right) = {\sum\limits_{i = 1}^{M - 1}\left. \left( t \right._{i + 1} - t_{i} \right)} = t_{M} - t_{1}$$

    We present the width (ranges from 0 to 1) standardized by the maximum width in the results: $$sW_{Z,j,v} = \frac{1}{t_{M} - t_{1}}W_{Z,j,v}$$

3.  *Average Titer Year (A*TY*)*: The average titer year is the center of mass of the curve with respect to strain isolation time, capturing all of an individual's titer values (i.e., the weighted average of their titers): $${ATY}_{j,v} = \frac{1}{AUC_{j,v}}{\sum\limits_{i = 1}^{M - 1}\frac{\left. \left( y \right._{i,j,v} + y_{i + 1,j,v} \right)}{2}}\frac{\left( t_{i + 1} + t_{i} \right)}{2}\left( t_{i + 1} - t_{i} \right)$$

In order to account for the impact of pre-birth strains, we calculated the metrics using post-birth strains and normalized with the number of post-birth strains (*M*~*post*~) in the main analysis. Exclusion of pre-birth strains was performed for each participant according to the year of birth. The normalized statistics are calculated as follows:

1.  *Normalized Area Under the Curve (nAUC)*: $$nAUC_{j,v} = \frac{1}{M_{post}}{\sum\limits_{i = 1}^{M_{post} - 1}{\frac{y_{i,j,v} + y_{i + 1,j,v}}{2}(t_{i + 1} - t_{i})}}$$

2.  *Normalized Width (nW)*: $$nW_{Z,j,v} = \frac{1}{t_{M_{post}} - t_{1}}{\sum\limits_{i = 1}^{M_{post} - 1}{W_{Z,j,v}\left( t_{i},t_{i + 1} \right)}}$$

3.  *Normalized Average Titer Year (nATY)*: $$nATY_{j,v} = \frac{1}{M_{post}nAUC_{j,v}}{\sum\limits_{i = 1}^{M_{post} - 1}{\frac{\left( y \right._{i,j,v} + y_{i + 1,j,v})}{2}\frac{\left( t_{i + 1} + t_{i} \right)}{2}(t_{i + 1} - t_{i})}}$$

For both normalized and unnormalized metrics, the changes in area under the curve and width between the visits were calculated as the difference between baseline and follow-up values of these metrics. In order to examine the temporal targeting of the changes in titers between the two visits, the changes in nATY ([Fig 4L](#ppat.1008635.g004){ref-type="fig"}) and ATY ([S2 Fig](#ppat.1008635.s003){ref-type="supplementary-material"}) are calculated using difference in titers: $$\Delta nATY_{j} = \frac{1}{\sum_{i = 1}^{M_{post} - 1}{\frac{\Delta y_{i,j} + \Delta y_{i + 1,j}}{2}\left( t_{i + 1} - t_{i} \right)}}{\sum\limits_{i = 1}^{M_{post} - 1}{\frac{\left( \Delta y \right._{i,j} + \Delta y_{i + 1,j})}{2}\frac{\left( t_{i + 1} + t_{i} \right)}{2}(t_{i + 1} - t_{i})}}$$ $$\Delta ATY_{j} = \frac{1}{\sum_{i = 1}^{M - 1}{\frac{\Delta y_{i,j} + \Delta y_{i + 1,j}}{2}(t_{i + 1} - t_{i})}}{\sum\limits_{i = 1}^{M - 1}{\frac{\left( \Delta y \right._{i,j} + \Delta y_{i + 1,j})}{2}\frac{(t_{i + 1} + t_{i})}{2}(t_{i + 1} - t_{i})}}$$

### Age pattern in antibody profiles {#sec020}

To account for the heterogeneous exposure history of participants at different ages ([Fig 2G--2I](#ppat.1008635.g002){ref-type="fig"}), we fitted generalized additive models (GAM) to the measured log-titers (*y*~*i*,*j*~) against all tested H3N2 strains incorporating a smoothed interaction term of age at sampling (*a*~*j*,1~) and year of the strains circulated (*t*~*i*~): $$y_{i,j} = s\left( {t_{i},a}_{j,1} \right)$$

We also fitted separate GAM to examine the non-linear association between each of summary analytic statistics (*I*~*j*,*v*~∈{*AUC*~*j*,*v*~,*ATY*~*j*,*v*~,*W*~*z*,*j*,*v*~}) mentioned in the above section and the ages of participants at baseline sampling (Figs [4](#ppat.1008635.g004){ref-type="fig"}, [S2](#ppat.1008635.s020){ref-type="supplementary-material"} and [S3](#ppat.1008635.s004){ref-type="supplementary-material"}) with the equation below: $$I_{j,v} = s\left( a_{j,1} \right)$$

We used the ratio of the average nAUC among people aged 50 years old to that among people aged 20 years old, to characterize the relative reduction of nAUC among people at 50 to the peak value. We derived the 95% CI of the ratio through 1000 bootstraps. In each bootstrap, we resampled the data set of observed nAUC and age at sampling, and refitted the above-mentioned GAM. We then calculated the ratio from each model prediction. With the same method, we also calculated the ratio of the average nW among people aged 50 years old to that among people aged 15 years old, at which the average nW is the greatest.

### Changes in antibody profiles between visits {#sec021}

The change of HAI titer is defined as the difference in the measured log-titers against tested H3N2 strain between the baseline and follow-up visits. We characterized the strain distribution among titers that were decreased, no change, two-fold increase and four-fold increased (seroconversion), respectively and compared such distribution with the underlying strain distribution (i.e. the number of titers of that strain divided the number of titers of all tested strains) ([S5 Fig](#ppat.1008635.s006){ref-type="supplementary-material"}). We fitted logistic regression of seroconversion (*c*~*i*,*j*~) on strains (*s*~*i*~, *as a categorical variable*) and adjusted for age at baseline sampling (*a*~*j*,1~) and prior log-titers (*y*~*i*,*j*,1~), to further examine the strain-specific odds of seroconversion (*α*~3~, [S4 Fig](#ppat.1008635.s005){ref-type="supplementary-material"}): $$logit\ \left( p({c_{i,j} = 1}) \right) = \alpha_{0} + \alpha_{1}a_{j,1} + \alpha_{2}y_{i,j,1} + \alpha_{3}s_{i}$$

We characterized the changes of HAI titers to four recent strains that were possibly circulating during our study period, i.e. A/HongKong/2014, A/Texas/2012, A/Victoria/2009 and A/Perth/2009. Distribution of changes by the number of strains that participants showed increased titers to and by individual strain was characterized, respectively ([S5 Fig](#ppat.1008635.s006){ref-type="supplementary-material"}). 95% confidence intervals were calculated by assuming a binomial distribution.

### Effects of pre-existing immunity on seroconversion to recent strains {#sec022}

We predicted the odds of seroconversion (*c*~*i*,*j*~) to one of four recent strains *i* (i.e. A/HongKong/2014, A/Texas/2012, A/Victoria/2009 or A/Perth/2009) by fitting logistic regression with predictors that reflect varying durations of exposure history and adjusting for age at baseline sampling (*a*~*j*,1~). In brief, we progressively included log-titer to the examined strain (*i*th, *y*~*i*,*j*,1~), log-titer to the strain prior to the examined strain (*i-1*th, *y*~*i*−1,*j*,1~) and one of the summary metrics (*I*~*j*,1~∈{*AUC*~*j*,1~,*ATY*~*j*,1~,*W*~*z*,*j*,1~}) that was calculated using strains isolated since the year of birth (or 1968 when including pre-birth strains) to the year before the *i-1*th strain was isolated. The model adjusting for the most complete exposure history is: $$logit\left( p(c_{i,j} = 1) \right) = \gamma_{0} + \gamma_{1}a_{j,1} + \gamma_{2}y_{i,j,1} + \gamma_{3}y_{i - 1,j,1} + \gamma_{4}I_{j,1},$$ and the model was fitted to each recent strain separately. Akaike information criterion (AIC) and Bayesian information criterion (BIC) were used to compare the performance of the models ([S6](#ppat.1008635.s007){ref-type="supplementary-material"} and [S13](#ppat.1008635.s014){ref-type="supplementary-material"} Figs). We present results of three models that included different predictors in [Table 1](#ppat.1008635.t001){ref-type="table"}; only including log-titer to strain *i* and strain *i-1* (Model 1), including log-titer to strain *i* and strain *i-1* and *AUC*~*j*,1~ (Model 2), and including log-titer to strain *i* and strain *i-1* and *W*~40,*j*,1~ (Model 3). We considered a linear effect of age on seroconversion to recent strains after adjusting for immunity to previous exposures in the main analyses as we hypothesized the latter could account for the non-linear effect of age ([Table 1](#ppat.1008635.t001){ref-type="table"} and [S6 Fig](#ppat.1008635.s007){ref-type="supplementary-material"}). We also considered a non-linear effect of age on seroconversion to recent strains in the sensitivity analyses and found qualitatively similar results with respect to the effect of other covariates in models ([S5 Table](#ppat.1008635.s006){ref-type="supplementary-material"} and [S13 Fig](#ppat.1008635.s014){ref-type="supplementary-material"}).

In order to further separate the direct effect of immunity of non-recent strains from the indirect effect, we conducted a mediation analysis based on the causal diagram shown in [S7 Fig](#ppat.1008635.s008){ref-type="supplementary-material"}. We first fitted the mediation model using a linear regression of pre-existing log-titer to strain *i* (*y*~*i*,*j*,1~) on pre-existing immunity to previous exposures (*I*~*j*,1~) and adjusting for age at baseline (*a*~*j*,1~). We then fitted the outcome model using a logistic regression of seroconversion to strain *i* (*c*~*i*,*j*~) on pre-existing log-titer to strain *i* (*y*~*i*,*j*,1~), pre-existing immunity to previous exposures (*I*~*j*,1~) and age at baseline (*a*~*j*,1~). We estimated total effect, average direct effect and average indirect effect using the "mediation" package with 1,000 bootstrap samples \[[@ppat.1008635.ref033]\]. We also fitted the outcome model with an additional interaction term between pre-existing log-titer to strain *i* and pre-existing immunity to previous exposures in order to account for the effect of their interactions on the mediation effects ([S8 Fig](#ppat.1008635.s009){ref-type="supplementary-material"}).

All analyses were performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), among which we fitted GAM using "mgcv" package \[[@ppat.1008635.ref034]\].

Supporting information {#sec023}
======================

###### 

(DOCX)

###### 

Click here for additional data file.

###### Representative individual profiles of HAI titer against H3N2 strains circulating over forty years among people aged 40 to 60 years.

(A-F): Antibody profile for each representative individual aged 40--60 years. Blue circles and red triangles represent the HAI titers against the tested strains at baseline and follow-up visit, respectively. Blue and red solid lines represent the smoothed HAI titers for serum collected from baseline and follow-up visit, respectively. Smooth splines of HAI titers on circulating years are shown in this figure for illustration purposes and not used in the subsequent analysis. Grey areas represent the baseline antibody profile. Purple and green areas indicate the increase and decrease of HAI titer at follow-up visit compared to baseline, respectively. Blue and red vertical blocks represent the duration for baseline and follow-up visit, respectively. Vertical dotted-dashed lines indicate the year of birth of the individual. Dashed and dotted lines represent the titer of 1:10 (detectable cutoff) and 1:40 (protective cutoff), respectively.

(TIF)

###### 

Click here for additional data file.

###### Area under the curve (AUC), average titer years (ATY) and width varying with age, using all tested strains.

Blue and red represent the AUC for the baseline and follow-up visit, respectively. Purple indicates the differences of indicators between the two visits. Solid lines are predictions from gam and the colored dashed lines represent the corresponding 95% confidence intervals. The sloping black dotted lines in panel J to L indicate the year of birth of participants. The dashed lines in panel J to L indicate the unweighted average isolation year of all strains.

(TIF)

###### 

Click here for additional data file.

###### Width of antibody profiles varying with age.

Widths were calculated using post-birth strains only. Panel A to C demonstrate width above titer 1:10, and Panel D to F demonstrate width above titer 1:40. Blue and red represent the indicators measured for serum collected in 2010 and 2014, respectively. Purple indicates the differences of indicators between the two visits. Solid lines are predictions from generalized additive model and the colored dashed lines represent the corresponding 95% confidence intervals. Results were calculated including all strains.

(TIF)

###### 

Click here for additional data file.

###### Odds of seroconversion by H3N2 strains.

Logistic regression models were fitted using age at sampling, prior titer and strains to predict the seroconversion. Coefficients for H3N2 strains are shown in the figure. The A/HongKong/1968 strain was set as reference.

(TIF)

###### 

Click here for additional data file.

###### Changes in titers to four recent strains.

\(A\) Distribution of changes in titers against recent H3N2 strains by the number of strains with increased titers. (B) Distribution of changes in titers against recent H3N2 strains by individual strain. We divided the changes in titers into four categories, i.e. decrease (green), no change (grey), two-fold increase (light purple) and four-fold change (seroconversion, dark purple).

(TIF)

###### 

Click here for additional data file.

###### Comparison of prediction performance of models including pre-existing immunity, assuming a linear effect of age.

Yellow and blue represents AIC and BIC, respectively. Dashed lines represent the AIC/BIC for models that only included titer to the examined strain *i*. Dotted lines represent the AIC/BIC for models that included titers to the examined strain *i* and the prior strain *i-1*. Dots are AIC/BIC for models including additional predictor of pre-existing immunity of strains up to strain *i-1*.

(TIF)

###### 

Click here for additional data file.

###### Directed acyclic graphs of hypothesized relations between immune responses to past strains, titer to recent strain and seroconversion to recent strain.

Indirect effect (*path a path b*): immune responses to previous strains have positive association between titer to strain *i* due to cross-reactions (*path a*), which has a negative association with seroconversion to strain *i* (*path b*). Direct effect (*path c*): effect of immune responses on seroconversion to strain *i* that was not mediated by titer to strain *i*. Total effect (*path a path b + path c*): combination of indirect effect and direct effect. Confounding effect (*path d*, *e* and *f*).

(TIF)

###### 

Click here for additional data file.

###### Mediation analysis of the effects of immune responses to previous strain on seroconversion to a recent strain.

Solid lines and filled squares represent the estimates from mediation analysis that did not consider interactions. Dashed lines and open circles represent the estimates from mediation analysis that considered interactions.

(TIF)

###### 

Click here for additional data file.

###### Changes in HAI titers between two visits.

Results are shown by subgroups of participants who had decreased (A), unchanged (B), increased (C) and four-fold increased (D) titers between the two visits, respectively.

(TIF)

###### 

Click here for additional data file.

###### Non-linear associations between age at sampling and seroconversion of four recent strains.

Models has been adjusted for titer to strain *i*, titer to strain *i-1*, and summary metrics.

(TIF)

###### 

Click here for additional data file.

###### Area under the curves (AUC), average titer years (ATY) and width varying with age, excluding participants who self-reported had been vaccinated against influenza.

Blue and red represent the AUC for the baseline and follow-up visit, respectively. Purple indicates the differences of indicators between the two visits. Solid lines are predictions from gam and the colored dashed lines represent the corresponding 95% confidence intervals. The sloping black dotted lines in panel J to L indicate the year of birth of participants. The dashed lines in panel J to L indicate the unweighted average isolation year of post-birth strains.

(TIF)

###### 

Click here for additional data file.

###### Association between pre-existing titer to individual strain and seroconversion to recent four strains.

Univariable coefficient (black) is estimated from univariable logistic regression of seroconversion to strain i on pre-existing titer to the strain listed in x-axis. Multivariable coefficient (red) is estimated from multivariable logistic regression of seroconversion to a strain *i* on pre-existing titer to the strain listed in x-axis, adjusting for age at sampling and titer to strain *i* and *i-1*.

(TIF)

###### 

Click here for additional data file.

###### Comparison of prediction performance of models including pre-existing immunity, assuming a non-linear effect of age.

Yellow and blue represents AIC and BIC, respectively. Dashed lines represent the AIC/BIC for models that only included titer to the examined strain *i*. Dotted lines represent the AIC/BIC for models that included titers to the examined strain *i* and the prior strain *i-1*. Dots are AIC/BIC for models including additional predictor of pre-existing immunity of strains up to strain *i-1*.

(TIF)

###### 

Click here for additional data file.

###### Distribution of H3N2 strains by changes in titers between two visits.

We divided the examined data (i.e. all data, or pre-existing titer is greater or less than 1:80) on titer changes into four subgroups, i.e. decreased (green), unchanged (grey), any fold increase (light purple, including four-fold or more increase) and four-fold or more increase (dark purple). Colored points and lines represent the distribution of H3N2 strains within each subgroup. Colored bars represent the distribution of H3N2 strains regardless of titer changes for the examined data. (A) all data; (B) a subset contains pre-existing titers ≤ 1:40; (C) a subset contains pre-existing titers \> 1:40. Insets D to F illustrate the distribution of changes in titers between two visits.

(TIF)

###### 

Click here for additional data file.

###### Association between pre-existing titer and seroconversion.

Univariable analysis of pre-existing titer on seroconversion. Coefficient was derived from univariable logistic regression of seroconversion to strain in x-axis on pre-existing titer to a strain listed in y-axis. Each cell represents an individual model. (B) Multivariable analysis of pre-existing titers on seroconversion. Coefficients were derived from multivariable logistic regression of seroconversion to a strain in x-axis on age at sampling and pre-existing titers to all strains listed in y-axis. Each column represents an individual model. Each cell within a column represents the association between pre-existing titer to the strain listed in the y-axis on the seroconversion to strain in x-axis, after adjusting for the pre-existing titers to the rest of the twenty strains. Asterisks indicate p ≤ 0.01.

(TIF)

###### 

Click here for additional data file.

###### Predicted probability of seroconversion and observed proportion of seroconversion by age group.

Models are fitted with a linear term on age, i.e. models used in [Table 1](#ppat.1008635.t001){ref-type="table"}. Age group was binned by 10 years. Horizontal lines represent the interquartile of predicted probability of seroconversion for the age group. Vertical lines represent 95% CI of the observed proportion of seroconversion derived from binomial distribution.

(TIF)

###### 

Click here for additional data file.

###### Predicted probability of seroconversion and observed proportion of seroconversion by age group, accounting for non-linear effect of age.

Models are fitted with a spline term on age, i.e. models used in [S9 Table](#ppat.1008635.s027){ref-type="supplementary-material"}. Age group was binned by 10 years. Horizontal lines represent the interquartile of predicted probability of seroconversion for the age group. Vertical lines represent 95% CI of the observed proportion of seroconversion derived from binomial distribution.

(TIF)

###### 

Click here for additional data file.

###### Comparison of demographic characteristics of participants.

(DOCX)

###### 

Click here for additional data file.

###### Geometric mean titer of tested H3N2 strains.

(DOCX)

###### 

Click here for additional data file.

###### Associations between pre-existing immunity and seroconversion to four recent strains, using titers to all tested strains.

(DOCX)

###### 

Click here for additional data file.

###### Associations between pre-existing average titer year or width above detectable threshold and seroconversion to four recent strains.

(DOCX)

###### 

Click here for additional data file.

###### Associations between and pre-existing immunity and seroconversion to four recent strains, considering the non-linear impact of age.

(DOCX)

###### 

Click here for additional data file.

###### Univariable logistic regressions of seroconversion to four recent strains on age and pre-existing immunity.

(DOCX)

###### 

Click here for additional data file.

###### Univariable analysis of predictors used to assess the association between pre-existing immunity and seroconversion to four recent strains.

(DOCX)

###### 

Click here for additional data file.

###### Comparison of demographic characteristics of participants who self-reported to have not been vaccinated against influenza.

(DOCX)

###### 

Click here for additional data file.

###### Associations between and pre-existing immunity and seroconversion to four recent strains, participants who reported never had been vaccinated against influenza.

(DOCX)

###### 

Click here for additional data file.

###### Associations between pre-existing immunity and seroconversion to four recent strains after accounting for sample collection time.

(DOCX)

###### 

Click here for additional data file.

10.1371/journal.ppat.1008635.r001
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10 Apr 2020

Dear Dr Yang,

Thank you very much for submitting your manuscript \"Life course exposures continually shape antibody profiles and risk of seroconversion to influenza\" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers\' comments.

I read the manuscript along with three reviewers. I share their concerns/comments and encourage the authors to take them onboard. In particular, Reviewer 1 highlights the very dense nature of the text. I think this paper was originally written for Science or Nature and this is still evident. It would be worth carefully expanding key topics. Reviewer 2 highlights important choices about the viruses that were included in the study and these issues should be addressed. Reviewer three raises interesting points about the timing of virus circulation during the lifetimes of study participants and these should be discussed in the main text.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers\' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Colin A. Russell

Guest Editor
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: Yang et al. analyze a large dataset of 777 paired serological samples to generate antibody profiles against 21 H3N2 strains, at two timepoints. The authors develop new metrics, nAUC, nW_z and nATY to measure the overall magnitude of antibody response, breadth of antibody response, and temporal center of mass of the antibody response, based on each individual's antibody profile. Empirically, many of the study's findings confirm results from past studies of antibody landscapes, or seroconversion, but the development of new metrics to quantify, analyze and simply talk about these complicated, multidimensional features of serological data is a significant step forward, and the importance of this work should not be taken for granted.

Overall, this is a thoughtful and well-written study. The authors have clearly done a lot of careful analysis and manage to present their findings with impressive clarity and conciseness, given how complicated it is to work with and interpret longitudinal serological data. I have a few comments, but overall, I found the study quite impressive.

Reviewer \#2: The manuscript describes innovative methods to quantify how antibody titres and titre rises across multiple temporally spaced influenza A(H3N2) virus strains differ between groups, in this case looking at age groups. The study was well designed to collect samples a from relatively large numbers of participants aged 2-86 Y at two time-points \~ 4-years apart, and measured serum HI antibody titres against 21 A(H3N2) viruses representing \~ 46 years of virus evolution in humans (1968 -- 2014). Antibody profiles were constructed by plotting each individuals HI titres against the 21 strains ordered chronologically. The main aim of the study is to derive metrics that may be used to summarize antibody profiles at different times, and then determine how profile metrics at time 1 may impact seroconversion and titre rise. Three equations or statistics were devised to characterize antibody profiles: "height" (AUC); "width" (summed time-intervals over which titres exceeded particular thresholds); and "temporal targeting of antibodies" (average year where antibody titres are concentrated). It was clear that people aged 40-60 years had relatively restricted antibody profiles in terms of AUC and width, which were centered on strains present around the midpoint of life, but it was less clear how these metrics impacted subsequent seroconversion and titre rise. Many models and tables were presented to show that some metrics improved models, albeit modestly compared to the effect of baseline homologous titre. However, the abstract, results and discussion do not clearly convey how important metrics were in terms of effects on immune responses.

Overall this is a nice study but the manuscript needs substantial re-writing, using more concise language, to convey the results and their meaning more effectively. Particular attention should be paid to the abstract. In addition, the supporting information is not set out in any particular order. The description of the supporting information does not follow the numbering of the figures and tables. It would be easier to follow the supporting information if it was broken into sections by the issue being addressed (E.g. Effects of normalization; Factors affecting seroconversion...., with the relevant supporting text, figures and tables adjacent to each other), and if there was some text to help the reader interpret the results that are being presented in each piece of supporting information. The manuscript may also be improved by carefully re-considering which topics to focus on and include in the main manuscript rather than in the supporting information.

Reviewer \#3: In this paper, authors collected serum samples of people aged 2 to 86 at two time points. The baseline sampling was done in 2009 to 2011 and follow-up was done in 2014-2015. As a result, 777 paired hemagglutination inhibition titers against 21 H3N2 strains were obtained. Antibody profiles of participants were generated and used to construct models that predict the risk of infections to recent strains. This study proposed three new metrics, AUC, Wz, ATY, aiming to determine antibody profile variation for predicting the risk of seroconversion. Using logistic regression model, effects of these metrics on seroconversion were discussed. However, the usefulness of the proposed models in predicting seroconversion is unclear.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: 1. My primary big-picture comment is that as currently written, the manuscript does not take nearly enough advantage of the flexible formatting guidelines provided by PLOS Pathogens. The text is certainly well written, but incredibly dense, possibly to the point of being difficult to follow for a non-influenza expert. Some of the main text figure panels (e.g. 2D-I) are rich with information, but not presented in the results section at all, which is a shame, and some of the results that are presented could be clearer with a bit more elaboration. It also seems a shame that the mediation analysis (Fig. S12) isn't mentioned until the Discussion, and buried deep in the Supplement.

2\. Can the authors elaborate a bit more on the fact that titers increased across the board, even to non-recent strains, from baseline to follow up (as shown clearly in Fig. 2)? This is presented as a result, and attributed to recent exposures. But the pattern is striking, and alternate explanations involving longer storage of the baseline samples, or storage issues affecting only the baseline samples, haven't been discussed. The results also leave me wondering if the baseline and follow-up samples were collected at different times of year, before and after the start of influenzas season, respectively, so that they can be thought of as analogous to acute and convalescent samples?

Edit: I'm only just now (after having read the study more than once), realizing that the baseline samples were collected shortly after the 2009 pandemic, at a time when H3N2 was not the dominant circulating subtype, and H3N2 titers had not been boosted in a while. Presumably there was a big H3N2 season prior to collection of most of the follow-up samples? This is an important point, which makes the observation that titers rose across the board make a lot more sense, and which should be made explicit in the text.

3\. The biological interpretation of nATY is lines 153-157 is very lucid and well-written. But I'm worried that this passage conflates the extreme case, presented for illustration (nATY tracks birth year), with a biological expectation. This extreme case could only come true if individuals developed and boosted titers only to the strain of first exposure, and were never again in their lifetimes able to generate a de novo response to new strains. We know empirically this is not how influenza immunity works, and I don't think anyone in the field would really expect nATY to track birth year perfectly---the fact that nATY moves away from birth year a little bit each year (as people are exposed to new strains and develop some de novo responses), isn't totally surprising and I'm not sure that this in itself logically rules out any alternatives. It would be great if the authors could clarify the biological expectations here, and elaborate a bit more on the observed patterns---does nATY asymptotically approach the unweighted average over time, or does it always remain somewhere between birth year and the unweighted average. Does nATY ever skew higher than the unweighted average?

A related point, which would lay the questions above to rest: Is the black dashed line showing unweighted average isolation year missing in Fig 3 J-L? Same comment in Fig. S10. I also see this dashed line is present in Fig. S2 J-L, but I'm not sure it's plotted correctly...here I see a flat line, but if the unweighted average only considers post-birth strains, I don't think it should be the same for all ages.

Reviewer \#2: 1. Timing of sample collection. Given that this study investigates factors that affect antibody titre change, the timing of sample collection, and how this may differ between individuals, could be very important, and should be taken into account. The periods over which samples were collected at baseline (2009-2011) and follow-up (2014-2015) are both long, such that potential virus exposure may differ between individuals and introduce experimental differences between antibody titre and titre-rise profiles.

2\. Viruses

2a. The methods should describe how were viruses were propagated -- eggs or cells and cell-type?

2b. Clade 3c.2a viruses such as HongKong/14 agglutinate turkey red blood cells very poorly and hence assays sensitivity may be poor. Was there any validation to determine whether this could account for relatively low titres against this virus in this study? In addition, some recent viruses can agglutinate via neuraminidase, which in turn can impair detection of HI antibodies. Were virus HA and NA genes sequenced and were titres tested with and without oseltamivir to determine whether titres could be affected by NA-agglutination.

2c. Clade 3c.3a viruses (Eg. A/Switzerland/9715293/13) circulated widely and were associated with large epidemics in 2014, so should be included.

3\. Models to understand antibody profile effects on seroconverion. Why was age effect considered to be linear in the main analysis when Figure 3 indicates that effects will not be linear? Why is i-1 strain titre included in all models when this had effects on seroconversion against A/Perth/2009 but not other strains. Could the situation with regard to i-1 strain reveal more complex interactions that depend on the strains involved? How do the authors interpret the relative impacts of AUC, width and ATY, other than that they were all positively associated with seroconversion? Are they all independently important or just related factors that indicate whether or not there is substantial existing immunity which provided a basis for boosting? There is some attempt to understand boosting versus interference (and ceiling) effects in relation to the opposite(?) effects of homologous-strain versus prior strain titres but this is not explained in much detail (line 226-229) and is hard to follow.

Reviewer \#3: Possible effect of H1N1 epidemics should be discussed. In the panels G and H in Figure 2, there is a \"saddle\" where we can see low titer to the H3N2 strains isolated during 1975-1980. This low titer might be related to H1N1 pandemic of the Russian flu in 1977. This point can be discussed in somewhere in the Discussion along with the concept of original antigenic sin or antigenic seniority.

For those who were born before 1968, there is no or less chance to be exposed to H3N2 viruses in their early life compared to those born after 1968. In Figure 3J and 3K, nATY is continuously declining up to the age around 50. The decrease in nATY stopped the age around 50 maybe because of no exposure to H3N2 viruses. However, in page Page 9, Line 157-158, authors wrote "Our empirical observations are more in line with the latter hypothesis", which assumes that \"all strains circulating in one's life were equally important\". This description should be modified and the possible interpretation should be added.

The authors claim that \"we found that participants who had higher immunity to previously exposed strains were more likely to experience seroconversion to recent strains after adjusting for homologous titer\" in Page 12, Line 221-223. However, it is not clear how Figure S11 and Table S10, S11 support this statement. The authors should clarify this point.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: 1. Overall, the writing in the manuscript is excellent, clear and easy to read. The Authors Summary, however, is a bit choppy in comparison to the rest of the text---consider text edits to tighten this up on revision.

2\. At their core, AUC and W_z seem to present different ways to measure the overall magnitude of an individual's antibody response. (i.e. how much of a high-responder is any given subject?) Is there any case where we should expect these quantities to diverge in the same individual? After developing and working with them, do the authors feel one is more useful than another?

Reviewer \#2: 1. The inclusion of A/HongKong/2014 as a recent strain is questionable since there may have been limited circulation of that virus prior to follow-up sampling in 2014-2015.

2\. The interpretation of width is somewhat limited due to the imposition of thresholds for defining the strains against which a response is detected. Can this metric be additionally weighted by titre for each strain? For example if the titre is 20 instead of 40 the width is increased by half that time interval instead of the full time interval.

3\. Multiple statements in the abstract are ambiguous as follows:

Line 38 -- should qualify the time period (\~ 4 Y) over which 97.8% had a titre rise.

Line 40 -- what does "recent strains exhibited the greatest variation" mean? Greatest titer rise,variation between age groups?

Line 41 -- qualify "adjusting for homologous titer" = at baseline?

Line 42 - qualify = seroconversion against recent strains?

4\. Results - Some of the key findings presented relate to deficits in antibody profiles among people aged 40 -- 60 years. In this regard, it would improve the manuscript if additional profiles for individuals from this age group are presented in Figure 1 or as supplementary information.

Figure 1 -- it may help to tie the manuscript together if AUC, width, and ATY values are also indicated for each individual shown.

Figure 2 -- as above, it may help to tie results together if age, AUC, width and ATY are indicated for the individuals shown as examples (panels A, E, I).

Line 111 -- referring to protective titres is controversial. Although 1:40 titres may be protective, or be associated with a 50% reduction in the risk of infection, this is not universal. It would be better to just say that 95.6% of participants had titres of at least 1:40 to at least one strain, and let the readers decide what that may mean.

Line 112: 116 -- it would be more meaningful to present GMT for post-birth, rather than all strains to understand differences between time 1 and time 2, and again interpretation of this result will depend upon the time of sample collection relative to virus transmission in the community.

Line 117 -- how was the age at time of isolation of the strain against which titers were highest determined from the multiple GAM fits? Can the GAM model R code be included in the supplement?

Line 147-152 -- This is very hard to follow. What is ratio to peak? Width is described in terms of percentage of strains against which titres were above threshold, whereas on line 149 the authors switch to fraction.

Figure S6 and S7 are included to justify that models to predict seroconversion are improved if titre to strain i, strain i-1 (variable improvement), AUC and W40 are all included, but what is the difference between Figure S6 and S7. It is clear that the values differ but there is no explanation as to why?

-- Consider substituting the term "risk" for capacity- or odds- of seroconversion to avoid the inference that factors such as a high AUC are a risk factor for being infected, when what you are really looking at is the capacity to produce antibodies.

5\. Discussion

Line 210 -- the authors suggest that antibody nautch and nWidth are relatively low among people in their 40-50s because other immune responses, which are not being measured, are preventing infections from occurring. However, their data indicates that 97.8% of people are having a titre rise which they surmise to represent infection. Please justify this inference considering the data presented, as well as data from other studies on A(H3N2) virus infection rates in different age groups.

Line 233 -- positive effects of titres to old strains on seroconversion against recent strains were only detectable in multivariate analysis.

6\. Supporting Information

-- There are many tables (S3, S4, S5, S6, S7) with different versions of models, mentioned in different parts of the manuscript. This makes it quite hard to follow what is going on, and what differs between models.

Fig S4 -- The caption should state that Odds Ratios were for comparison with seroconversion against HK/1968. It is not sufficient to state this in the main text only.

Fig S5 -- what do the colours mean?

7\. Minor typographical or grammatical errors

Line 372 -- the each

Line 377 -- decrease should be decreased

Line 603 --among for

Line 616 -618 - of people aged 40-50 years (xxxx) of participants who

Line 644 -- When fitted logistic regressions of seroconversions on recent strains with age at ....(rewrite this sentence).

Line 656 -- antigenically relatives

Reviewer \#3: Page 5. Line 70-71:

Add reference to other works such as

Nachbagauer R, Choi A, Hirsh A, et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol. 2017;18(4):464--473. doi:10.1038/ni.3684

Page 6. Line 95:

The term seroconversion should be defined precisely. Use an independent sentence to define what is seroconversion.

Page 7. Line 107-108:

Year 2009 has two strains (i.e. A/Perth/2009, A/Victoria/2009). The reason why two strains were included should be explained.

Page 7. Line 110:

(Fig 1, A and C) should be (Fig 1, A-C), because Fig 1 B also contains \"pre-birth strains\".

Page 7. Line 113:

GMTs of pre-birth strains should be shown in Table S2.

Page 7. Line 116-117:

The authors wrote, "Participants had the highest titer to strains that were isolated within the first decade of their life (4.3 years; IQR, 2.0 to 6.9 years across strains) (Fig. S1)". However, it is difficult confirm this description only form Fig. S1. Is it possible to have another representation to visualize this claim? It is also not clear from which table the median and IQR were derived.

Page 7. Line 117-118:

It is not clear from which Table the statistics of GMTs of recent strains and that of non-recent strains for baseline and follow-up visits were derived. It seems to be Table S2. If so, the table should be referred in the body text.

Page 8. Line 136:

\"Non-normalized analysis included in SI Materials and Methods\" should be \"\...in S1 Appendix\".

Page 9. Line 143:2.1 (95% CI, 1.9 to 2.4) and 1.7 (95% CI, 1.5 to 1.9)

The method used for the calculation of these confidence intervals of odds ratio should be clarified.

Page 9. Line 162:

In the statement \"Fig. 2C and f\", \"F\" should be in capital letter.

Page 9. Line 163:

The author wrote \"73.7% showed a 4-fold or greater titer increase (seroconversion) to one or more (Fig. 2I)\". However, it is difficult to confirm this proportion from Fig. 2I.

Page 11. Line 190-193:

The sentence \"Based on the impact of seroconversion and transient antibody dynamics\...\" is difficult for readers to understand. It would be better to break it down into smaller and simpler sentences to describe the findings.

Page 11. Line 194:

Fig. 2F could not demonstrate that the increased antibody titers were those against non-recent strains. It may be better to refer to Fig. 2C instead.

Page 12. Line 211:

Grammatical error of the phrase \".., could preventing people\...\".

Page 12. Line 229:

\"detailed in S Appendix\" should be \"detailed in S1 Appendix\"

Page 14. Line 712:

The author mentioned \"Table S18\". This should be \"Table S8\"

Page 16. Line 295:

There should be a space between \"A/Wuhan/1995,\" and \"A/Victoria/1998\".

Page 17. Line 327:

The values are added from i=1 to M-1. It is not clear why you stop at M-1 instead of M. Please describe the reason. Is it related to the two strains in 2009?

Page 20. Line 369: GAM

Detailed information of the model is needed, i.e. the distribution and link function used in GAM.

Page 24. Line 441-442:

Citation of Francis T 1960 contains its title twice.

Page 33. Table 1:

The definitions of Model 1, 2, and 3 are not clear. Please describe which are Model 1, 2, and 3 in the Method Section. Explanations on how to interpret values are needed for general readers. For instance, what does it mean when values are larger than 1 or smaller than 1.

Page 38. Line 659:

\"per-existing\" should be \"pre-existing\".

Page 41. Line 716:

Grammatical error of the phrase \"Vaccination status of influenza seems not affect\...\".

Page 45. Line 747-749:

It seems that the coefficient was normalized by comparing to A/HongKong/1968 as written in Line 165 in Page 10. If so, the figure legend should be collected to indicate this.

Page 46. Line 753:

\"changes in tiers\" should be \"changes in titers\".

Page 46. Fig. S5.

There is no explanation for the different colors in this figure.

Page 47-48. Fig. S6-S7:

Explain the difference between Figure S6 and S7. The Figures look different but AIC and BIC values are the same. Figure legends are also the same.

Page 52. Fig. S11b:

Figure legend is not clear. If each column represents an individual model as stated, it is unclear what each row within the column means.

Page 61. Table S1:

It is not clear what Pa means.

Supplementary Information:

There are so many supplementary figures and tables. The reviewer recommends providing only figures and tables essential for this manuscript.
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Dear Dr Yang,

We are pleased to inform you that your manuscript \'Life course exposures continually shape antibody profiles and risk of seroconversion to influenza\' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.
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